Measurement of Human Cytomegalovirus Loads by Quantitative Real-Time PCR for Monitoring Clinical Intervention in Transplant Recipients
Open Access
- 1 January 2003
- journal article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 41 (1) , 187-191
- https://doi.org/10.1128/jcm.41.1.187-191.2003
Abstract
Quantitative monitoring of human cytomegalovirus (HCMV) infection is helpful in determining appropriate antiviral management of transplant recipients. Quantitative PCR technologies have demonstrated accuracy in measuring systemic HCMV loads. A total of 298 consecutive whole-blood specimens submitted to the Clinical Virology Laboratory at Vanderbilt University Medical Center from 15 February to 31 October 1999 were included in the study. In addition to a qualitative colorimetric microtiter plate PCR assay (MTP-PCR) and a semiquantitative pp65 antigenemia assay, each specimen was measured for HCMV loads by a quantitative PCR assay performed on an ABI PRISM 7700 Sequence Detection System (TaqMan). Compared to results of the MTP-PCR, the sensitivity, specificity, positive predictive value, and negative predictive value were 70.5, 97.5, 87.8, and 92.8% for the antigenemia assay and were 96.7, 92.0, 75.6, and 99.1% for the TaqMan assay, respectively. There was a high correlation between antigenemia values and HCMV loads as determined by the TaqMan (r = 0.989; P < 0.001). Antigenemia values of 0, 1 to 10, 11 to 100, 101 to 1,000, and over 1,000 positive cells per 2 × 105 leukocytes corresponded to median HCMV loads measured by TaqMan of 125, 1,593, 5,713, 16,825, and 5,425,000 copies/ml, respectively. Corresponding to antigenemia values of 1 to 2, 10, and 50 positive cells per 2 × 105 leukocytes, HCMV viral loads of 1,000, 4,000, and 10,000 copies/ml are proposed as cutoff points for initiating antiviral therapy in patient groups with high, intermediate, and low risk of CMV diseases.Keywords
This publication has 50 references indexed in Scilit:
- Role of the Laboratory in Diagnosis and Management of Cytomegalovirus Infection in Hematopoietic Stem Cell and Solid-Organ Transplant RecipientsJournal of Clinical Microbiology, 2002
- Comparative Quantitation of Cytomegalovirus (CMV) DNA in Solid Organ Transplant Recipients with CMV Infection by Using Two High-Throughput Automated SystemsJournal of Clinical Microbiology, 2001
- Quantification of Human Cytomegalovirus DNA in Bone Marrow Transplant Recipients by Real-Time PCRJournal of Clinical Microbiology, 2001
- Diagnosis and Monitoring of Human Cytomegalovirus Diseases in Patients with Human Immunodeficiency Virus Infection by Use of a Real‐Time PCR AssayClinical Infectious Diseases, 2001
- Comparison of Quantitative and Qualitative PCR Assays for Cytomegalovirus DNA in PlasmaJournal of Clinical Microbiology, 2001
- Prevention of Cytomegalovirus Disease in Recipients of Solid-Organ TransplantsClinical Infectious Diseases, 2001
- Cytomegalovirus (CMV) DNA Load in Plasma for the Diagnosis of CMV Disease before Engraftment in Hematopoietic Stem‐Cell Transplant RecipientsThe Journal of Infectious Diseases, 2001
- PLASMA POLYMERASE CHAIN REACTION FOR CYTOMEGALOVIRUS DNA AFTER ALLOGENEIC MARROW TRANSPLANTATIONTransplantation, 1997
- PATTERNS OF VIREMIA IN LIVER TRANSPLANT RECIPIENTS WITH SYMPTOMATIC CYTOMEGALOVIRUS INFECTIONTransplantation, 1997
- High levels of circulating cytomegalovirus DNA reflect visceral organ disease in viremic immunosuppressed patients other than marrow recipients.Journal of Clinical Investigation, 1992